Key Points
- Insider sale: Director Steven Coen sold 33,171 shares on April 13 at an average price of $6.41 for a total of $212,626.11 to cover tax withholding on vested awards, cutting his stake by about 39.96% to 49,849 shares (valued at $319,532.09).
- Stock snapshot: Ginkgo Bioworks shares recently traded around $7.73, with a 52‑week range of $5.37–$17.58, a market cap of ~$478.6M, a 50‑day/200‑day moving average of $7.56/$9.42, and a beta of 1.56.
- Analyst and financials: The consensus rating is "Reduce" with a $8.50 target after several price cuts; the company reported a -$1.42 EPS (better than estimates) but missed revenue and still shows negative margins and ROE.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Steven Coen sold 33,171 shares of the stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $6.41, for a total value of $212,626.11. Following the completion of the transaction, the insider directly owned 49,849 shares of the company's stock, valued at $319,532.09. This represents a 39.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ginkgo Bioworks Stock Performance
Shares of NYSE:DNA opened at $7.73 on Wednesday. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.37 and a 52-week high of $17.58. The firm has a market capitalization of $478.64 million, a P/E ratio of -1.37 and a beta of 1.56. The stock has a 50 day moving average price of $7.56 and a 200-day moving average price of $9.42.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($1.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.38. Ginkgo Bioworks had a negative return on equity of 52.82% and a negative net margin of 183.81%.The firm had revenue of $33.40 million during the quarter, compared to analyst estimates of $37.57 million. On average, equities analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on DNA. BTIG Research reduced their price objective on Ginkgo Bioworks from $9.00 to $5.00 and set a "sell" rating for the company in a research report on Thursday, March 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Ginkgo Bioworks in a research report on Wednesday, January 21st. TD Cowen reduced their price objective on Ginkgo Bioworks from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, January 8th. Finally, Wall Street Zen raised Ginkgo Bioworks from a "sell" rating to a "hold" rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Ginkgo Bioworks currently has a consensus rating of "Reduce" and a consensus target price of $8.50.
Get Our Latest Report on Ginkgo Bioworks
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quarry LP bought a new position in Ginkgo Bioworks during the 3rd quarter valued at approximately $29,000. Raymond James Financial Inc. bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth $29,000. Strs Ohio bought a new stake in shares of Ginkgo Bioworks in the 3rd quarter worth $44,000. Strategic Advocates LLC increased its holdings in shares of Ginkgo Bioworks by 808.9% in the 4th quarter. Strategic Advocates LLC now owns 4,381 shares of the company's stock worth $36,000 after purchasing an additional 3,899 shares in the last quarter. Finally, State of Wyoming bought a new stake in shares of Ginkgo Bioworks in the 3rd quarter worth $74,000. Institutional investors own 78.63% of the company's stock.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.
The company's services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
